Study finds more U.S. prostate cancer patients choosing active surveillance

Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

Researchers from UC Davis Comprehensive Cancer Center is testing a drug called niraparib (Zejula), given before prostate cancer surgery. Researchers think it could enable more personalized treatments—especially for men with prostate cancer that has specific DNA repair gene mutations.

June 06, 2025

Vol.51 No.22

Drugs & Targets

FDA approves Nubeqa for metastatic castration-sensitive prostate cancer

FDA approved the oral androgen receptor inhibitor Nubeqa (darolutamide) for the treatment of adult patients with metastatic castration-sensitive prostate cancer, which is also known as metastatic hormone-sensitive prostate cancer.

June 06, 2025

Vol.51 No.22

Clinical Trials & Tribulations

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising.

May 23, 2025

Vol.51 No.20

By Peter Nelson

Funding Opportunities

DOD prostate cancer research program FY25 funding opportunities

The Full-Year Continuing Appropriations and Extensions Act of 2025 provides $650M in funding for the CDMRP. Congress provided further guidance for CDMRP program-level funding, including funding for the Prostate Cancer Research Program. The FY25 PCRP intends to support innovative, high-impact prostate cancer research.

May 23, 2025

Vol.51 No.20

Clinical Roundup

Genetic mutation in some Ashkenazi Jewish men may be linked to higher prostate cancer risk, study shows

A Johns Hopkins Medicine-led research team has identified a recurrent frameshift mutation, called F722fs, in the MMS22L gene among men of Ashkenazi Jewish ancestry that is associated with a higher risk of prostate cancer and increased sensitivity to a specific anticancer therapy.

May 23, 2025

Vol.51 No.20

Clinical Roundup

Shorter radiation therapy after prostate surgery safe, UCLA study finds

For men who undergo a radical prostatectomy for the treatment of prostate cancer, post-surgery radiation therapy can play a vital role in reducing the risk of recurrence.

May 16, 2025

Vol.51 No.19

Study finds more U.S. prostate cancer patients choosing active surveillance

YOU MAY BE INTERESTED IN

Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

FDA approves Nubeqa for metastatic castration-sensitive prostate cancer

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

DOD prostate cancer research program FY25 funding opportunities

Genetic mutation in some Ashkenazi Jewish men may be linked to higher prostate cancer risk, study shows

Shorter radiation therapy after prostate surgery safe, UCLA study finds

Renew today!

Subscriber content

Never miss an issue!

Login

Study finds more U.S. prostate cancer patients choosing active surveillance

YOU MAY BE INTERESTED IN

Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

FDA approves Nubeqa for metastatic castration-sensitive prostate cancer

Biden’s diagnosis is unfortunate but—statistically—not surprisingOf the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

DOD prostate cancer research program FY25 funding opportunities

Genetic mutation in some Ashkenazi Jewish men may be linked to higher prostate cancer risk, study shows

Shorter radiation therapy after prostate surgery safe, UCLA study finds

Never miss an issue!

Login

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime